Sign in

Endometrial cancer: trials that stopped early

Trials on Endometrial cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

57 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Aug 2025.

    Ended
    May 2025
    Phase
    Phase 2/3
    Run by
    University Health Network, Toronto
    Registry record
    NCT04159155
  2. Terminated

    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2025.

    Ended
    Apr 2025
    Phase
    Phase 1
    Run by
    Numab Therapeutics AG
    Registry record
    NCT06299163
  3. Terminated

    Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

    Reason given in the registry

    “Patients were recruited during screen phase but fewer patients met criteria.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jul 2025.

    Ended
    Jun 2025
    Phase
    Phase 2
    Run by
    National Cheng-Kung University Hospital
    Registry record
    NCT04030429
  4. Terminated

    A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

    Reason given in the registry

    “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.

    Ended
    Jun 2024
    Phase
    Phase 1/2
    Run by
    Hutchmed
    Registry record
    NCT04577963
  5. Terminated

    A Biomarker Screening Protocol for Participants With Solid Tumors

    Reason given in the registry

    “Pipeline Reprioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.

    Ended
    Feb 2025
    Run by
    Lyell Immunopharma, Inc.
    Registry record
    NCT05891197
  6. Terminated

    A Study to Investigate LYL797 in Adults With Solid Tumors

    Reason given in the registry

    “Pipeline Reprioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Lyell Immunopharma, Inc.
    Registry record
    NCT05274451
  7. Suspended

    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.

    Ended
    Sept 2025
    Phase
    Phase 1
    Run by
    NextPoint Therapeutics, Inc.
    Registry record
    NCT05958199
  8. Terminated

    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

    Reason given in the registry

    “Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2025.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04152018
  9. Terminated

    Bariatric Education for Women With Obesity and Endometrial Cancer

    Reason given in the registry

    “No Surgeon to perform the operations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.

    Ended
    Apr 2025
    Run by
    University of Oklahoma
    Registry record
    NCT05396794
  10. Withdrawn

    Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

    Reason given in the registry

    “IMP owner decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.

    Ended
    Apr 2026
    Phase
    Phase 1/2
    Run by
    Vall d'Hebron Institute of Oncology
    Registry record
    NCT06385548
  11. Terminated

    A Study of SGN-ALPV in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT05229900
  12. Terminated

    A Study of SGN-STNV in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT04665921
  13. Withdrawn

    A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

    Reason given in the registry

    “A business decision was made to not initiate this study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Jan 2025.

    Phase
    Phase 1
    Run by
    Astellas Pharma Global Development, Inc.
    Registry record
    NCT06681870
  14. Terminated

    Oral AMXT 1501 Dicaprate in Combination With IV DFMO

    Reason given in the registry

    “Required re-formulation of DFMO from IV to capsule to maintain safety”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Aminex Therapeutics, Inc.
    Registry record
    NCT05500508
  15. Withdrawn

    Niraparib in High-grade Endometrial Cancer Trial

    Reason given in the registry

    “Unable to obtain funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Dec 2024.

    Ended
    Jan 2026
    Phase
    Early phase 1
    Run by
    Sir Mortimer B. Davis - Jewish General Hospital
    Registry record
    NCT05289648
  16. Withdrawn

    Laser Treatment of Genito-urinary Syndrome in Women

    Reason given in the registry

    “Hospital terminated treatment with laser”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2024.

    Run by
    Herning Hospital
    Registry record
    NCT03238053
  17. Withdrawn

    TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

    Reason given in the registry

    “Lack of accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Brown University
    Registry record
    NCT05655598
  18. Terminated

    A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

    Reason given in the registry

    “Lack of Funding - no safety issue with Drug; Company Permanently Closed”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.

    Ended
    Jun 2024
    Phase
    Phase 1/2
    Run by
    Elucida Oncology
    Registry record
    NCT05001282
  19. Terminated

    Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

    Reason given in the registry

    “This was a national survey of physicians. Per the protocol, they were only allowed to be contacted twice and they received less surveys back than anticipated.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Apr 2024.

    Ended
    Feb 2024
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT05877404
  20. Withdrawn

    PET/MRI in Endometrial Cancer

    Reason given in the registry

    “Unable to enroll patients to study”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2024.

    Ended
    Feb 2026
    Run by
    Massachusetts General Hospital
    Registry record
    NCT05390021
  21. Withdrawn

    Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

    Reason given in the registry

    “The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with lerociclib.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2023.

    Ended
    Mar 2025
    Phase
    Phase 3
    Run by
    EQRx International, Inc.
    Registry record
    NCT05712941
  22. Withdrawn

    Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

    Reason given in the registry

    “Slow Accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Feb 2023.

    Phase
    Phase 2
    Run by
    Haider Mahdi
    Registry record
    NCT05419817
  23. Suspended

    Guangzhou Women's Health Cohort Study (GWHCS)

    Reason given in the registry

    “Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2023.

    Ended
    Aug 2026
    Run by
    Guangzhou Women and Children's Medical Center
    Registry record
    NCT05506800
  24. Suspended

    A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

    Reason given in the registry

    “Company decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2022.

    Ended
    Jan 2024
    Phase
    Phase 1/2
    Run by
    Clovis Oncology, Inc.
    Registry record
    NCT04042116
  25. Withdrawn

    Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

    Reason given in the registry

    “Salarius discontinued support”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Mar 2022.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    HonorHealth Research Institute
    Registry record
    NCT04611139
  26. Suspended

    Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors

    Reason given in the registry

    “Study stopped due to COVID-19 pandemic, as conducting a behaviour-change programme in groups was not recommended to prevent the spread of the virus.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2021.

    Ended
    Nov 2025
    Run by
    Brazilian National Cancer Institute
    Registry record
    NCT03095664
  27. Withdrawn

    Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

    Reason given in the registry

    “PI is leaving institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Nov 2020.

    Phase
    Phase 2
    Run by
    Case Comprehensive Cancer Center
    Registry record
    NCT04197219

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.